Kukje Pharma Co Ltd

Kukje Pharma maintains a conservative capital structure with a debt-to-equity ratio of 0.31, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.09, suggesting it can cover short-term obligations but with limited buffer. Free cash flow of KRW 4,295,466,830 and operating cash flow of KRW 5,835,456,500 support operational flexibility, though net cash is negative after subtracting total debt. Profitability metrics show a return on equity of 5.83% and return on assets of 3.13%, both below the typical thresholds for high-margin pharmaceutical firms. Operating income of KRW 6,168,786,350 and net income of KRW 5,697,660,530 reflect moderate profitability, with gross profit of KRW 93,644,813,620 indicating strong cost control in production. The company's revenue is concentrated in pharmaceutical manufacturing, with no disclosed segment breakdown, and geographic exposure is primarily within South Korea, as no international revenue figures are provided. This lack of diversification may increase vulnerability to domestic market fluctuations. Growth trajectory is not explicitly outlined in the financial data, but the company's capital expenditure of -KRW 3,868,781,040 suggests a focus on cost optimization rather than expansion. The absence of significant revenue growth or new product launches in the data implies a stable but potentially stagnant growth outlook. Risk factors include medium liquidity risk due to the current ratio and negative net cash position, as well as potential dilution from the company's capital structure, though the risk is currently assessed as low. No recent events or filings are disclosed in the provided data, limiting insight into strategic shifts or regulatory changes.